GlassScriptPhysician profile
Allen D Long
NPI 1578772828
$8,101.57
in general payments reported to CMS, 2019-2025
44 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $1,114 · 2023: $2,531 · 2024: $2,286 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,389 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,389.22 |
| Travel and Lodging | $225.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $897.30 | 2021-2025 | Ultomiris, Soliris |
| Abbvie INC. | $824.90 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $628.71 | 2022-2025 | Nuplazid |
| Relievant Medsystems, INC. | $506.17 | 2023 | Intracept |
| Ucb, INC. | $493.59 | 2023-2025 | Briviact, Zilbrysq, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $411.00 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $407.05 | 2021-2025 | Hyqvia, Gammagard |
| Tg Therapeutics, INC. | $403.36 | 2023-2025 | |
| Genentech USA, INC. | $373.92 | 2021-2024 | Ocrevus, Evrysdi |
| Janssen Pharmaceuticals, INC | $307.07 | 2023-2024 | Xarelto |
| Neurelis, INC. | $303.09 | 2022-2025 | Valtoco |
| Alnylam Pharmaceuticals INC. | $262.93 | 2022-2025 | Onpattro, Amvuttra |
| Lundbeck LLC | $236.54 | 2022-2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $182.80 | 2023-2024 | Rexulti, Nuedexta |
| Medtronic, INC. | $168.55 | 2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $166.32 | 2023-2024 | Mavenclad |
| Genzyme Corporation | $164.22 | 2021-2025 | |
| Celgene Corporation | $133.55 | 2023 | Zeposia |
| Merz Pharmaceuticals, LLC | $121.27 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| E.R. Squibb & Sons, L.L.C. | $120.71 | 2023 | Zeposia |
| Pacira Pharmaceuticals Incorporated | $115.79 | 2022 | |
| Argenx US, INC. | $115.33 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Saluda Medical Americas, INC. | $109.14 | 2024 | Evoke |
| Lilly USA, LLC | $108.63 | 2023-2025 | Amyvid, Kisunla |
| Jazz Pharmaceuticals INC. | $74.66 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $67.61 | 2025 | Purified Cortrophin Gel |
| Csl Behring | $51.91 | 2025 | Hizentra |
| Acorda Therapeutics, INC | $46.13 | 2023-2024 | Inbrija |
| Biogen, INC. | $35.12 | 2024-2025 | Skyclarys |
| Amgen INC. | $24.64 | 2025 | Uplizna |
| Integra Lifesciences Corporation | $24.16 | 2024 | Duraseal Exact Spinal Sealant System, Codman Certas, Cusa Clarity |
| Tanabe Pharma America, INC. | $23.12 | 2023 | |
| Horizon Therapeutics Plc | $19.51 | 2021 | |
| Corium, LLC | $18.22 | 2023 | Adlarity |
| Nalu Medical, INC. | $17.67 | 2022 | |
| Novo Nordisk INC | $17.54 | 2024 | Wegovy |
| Viz.Ai, INC. | $16.83 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $16.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.12 | 2023 | |
| Springworks Therapeutics, INC. | $15.06 | 2025 | |
| Cala Health, INC. | $14.92 | 2025 | Cala Kiq |
| Impel Pharmaceuticals INC. | $14.28 | 2023 | Trudhesa |
| Allergan, INC. | $13.69 | 2021 | |
| Curonix LLC | $13.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.